Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim report July-September 2018

Mölndal, November 8, 2018 – Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the third quarter 2018.Important events during the third quarter · In July, Vicore announced it had entered into an agreement to acquire INIM, a Swedish biopharmaceutical company developing a new local treatment for severe rare interstitial lung diseases. Before the acquisition, HealthCap VII L.P. owned 85% of INIM and, following the transaction, became the largest shareholder in Vicore Pharma Holding AB with 30.4% of the shares · In August, an extraordinary general meeting was

Invitation to presentation of Opus’ Q3 2018 report

Opus Group AB (publ) will release its report for the third quarter 2018 before themarket opens on Thursday, November 15, 2018. CEO Lothar Geilen and CFO LinusBrandt will present the company’s results on the same day at 14:30 CET.The presentation will be held in English. To join the webcast please click on the following link: https://edge.media-server.com/m6/p/7tptwj6u To connect to the conference call please dial in 5-10 minutes prior to the start time, using the conference Confirmation Code below. Confirmation Code: 1713603 Participants, Local - Stockholm, Sweden: +46 (0) 8

Moberg Pharma’s nomination committee appointed

STOCKHOLM, November 8th, 2018 – In accordance with the resolution of the Annual General Meeting on May 15th, 2018, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the fourth largest shareholder/group of

Nomination Committee appointed in Green Landscaping Holding AB

In accordance with the principles adopted by the general meeting in Green Landscaping AB the Nomination Committee shall be comprised of the Chairman of the Board of Directors and three members appointed by the three shareholders with the largest number of votes in the company. If either of the shareholders with the largest number of votes waives their right to appoint a member, the shareholder with the next largest shareholding shall be offered the opportunity to appoint a member.The Nomination Committee ahead of the 2019 AGM comprises the following members: · Marcus Trummer (appointed

Interim report January-september 2018

Interim period January–September 2018 · Net asset value amounted to SEK 125.2 per share, compared to SEK 111.7 at the beginning of year, which corresponds to an increase of 12.1 per cent. Net asset value per share increased 13.9 per cent including dividends paid. · Bure’s net asset value was SEK 8,664M compared to SEK 7,743M at the beginning of the year. · Total return on the Bure share was 18.3 per cent compared to the SIX Return Index that increased 11.3 per cent. • Consolidated profit after tax was SEK 997M (1,864). Earnings per share amounted to SEK 14.39 (26.88). Third

OrganoClick AB (publ) publishes its interim report for third quarter 2018

"Within the product area biobinders for nonwoven, a globally leading producer of textile interlinings launched an eco-collection in September in which our biobased binder is a key component which replaces the currently used oil based plastic binders. Textile interlinings are used as linings and stiffening materials in all jackets, suits, shirts, etc and are made of nonwovens, woven or knitted textiles which are mechanically modified with binders. Our customer predict to receive their first bigger orders during 2019." Translation from CEO Mårten Hellbergs comments to the Interim Report.

Japanese online recruiter Mynavi expands agreement for use of Cxense

Oslo, Norway – 8 November 2018 – Cxense ASA (OSE: CXENSE) today announced that Mynavi Corporation (Mynavi), a Japanese publisher of online recruitment-, student-, real-estate- and news services signed an agreement to renew and extend the use of Cxense solutions. In addition to its use of Cxense Data Management Platform (DMP) with Intelligent Personalization, Mynavi will implement Conversion Engine.Tokyo-based Mynavi has 9,400 employees and operates a wide range of online recruitment and career services targeting various age groups, ranging from graduates to facilitating employment of the

Capio awarded an extension of the contract to run Capio S:t Göran’s hospital and two acute geriatric contracts in Stockholm

The Stockholm County Council (SCC) has resolved to extend Capio’s contract to run Capio S:t Göran’s hospital from January 2022 to January 2026. At the same time the SCC resolved to trust Capio to continue to run the acute geriatric activities at Nacka hospital and awarded Capio a new contract to run the acute geriatric activities at Löwenströmska hospital. Annual net sales of the S:t Göran contract is approximately SEK 2 billion while the two acute geriatric contracts have combined annual net sales of approximately MSEK 250.Capio has successfully been running hospital care at S:t Göran’s

Initiator Pharma signs option agreement for Phase 2 ready drug candidate

Initiator Pharma A/S, a biotech company that is developing a novel treatment of erectile dysfunction today announced that it has signed an option agreement with Saniona AB, for a phase 2 ready drug candidate.Initiator Pharma has secured a 1 year exclusive option agreement for a Phase 2 ready compound, AN788, that has previously undergone clinical development for anxiety and depressive disorders but it has never be tested in a Phase 2 clinical trial. Initiator Pharma intends to reposition the drug candidate based on our expertise with monoamine-reuptake inhibitors. The drug candidate has

Aspire Global’S Interim Report For The Third Quarter 2018 – Consistent Strong Organic Growth

THIRD QUARTER (JULY-SEP 2018)• Revenues increased by 48% to €28.6 million (19.3)• B2B Revenues increased by 50.5% to €15.2 million (10.1)• EBITDA increased by 48% to €6.2 million (4.2)• EBITDA margin amounted to 21.6% (21.6%)• EBIT increased to €5.7 million (3.9)• Earnings after tax from continued operations increased to €4.8 million (3.4)• Earnings per share after tax from continued operations increased to €0.11 (0.08)• First time depositors (FTDs) increased by 51% to 96.6 thousand (63.9) INTERIM PERIOD (JAN-SEP 2018)• Revenues increased by 36% to €71.7 million (52.8)

Polygiene AB (publ.) Interim Report 1 July–30 September 2018

New product launch, continued improved earnings and positive cash flowQ3 in brief · In the third quarter, net sales amounted to MSEK 18.3 (19.0), which corresponds to a decrease of 3.7% compared to the same period last year. · Operating profit/loss (EBIT) for the period amounted to MSEK 0.6 (0.7). · The cash flow for the third quarter was positive MSEK 0.4 (-1.9). · Gross margin amounted to 70.1% (70.1%). · The company extends its product portfolio with new, patented technology. · The organization is growing in North America as part of the new marketing strategy.

AZN: Year-to-Date and Q3 2018 Results

AstraZeneca PLC 8 November 2018 07:00 GMT Year-to-Date and Q3 2018 Results AstraZeneca Returns to Sales Growth; New Medicines and Emerging Markets Lead the Way Product Sales increased by 4% in the year to date (2% at CER1), supporting full-year guidance. For the quarter, Product Sales increased by 8% (9% at CER), driven by the strong performance of new medicines2 (+85%, +86% at CER) and the sustained strength of Emerging Markets (+12%, +16% at CER). Oncology sales increased by 56% in the quarter (57% at CER); China and US sales increased by 32% and 25%, respectively. The

Finnish company rewarded with Global Road Achievement Award by International Road Federation

Roadscanners, an innovative traffic infrastructure asset management company from Rovaniemi, Finland, has been recognized by the International Road Federations (IRF) and given the Global Road Achievement Award in 2018. The award was announced on the evening of November 7th in Las Vegas at the 70th anniversary gala of the IRF. This is the first time it has been awarded to Finland.The prize was awarded for the PEHKO 2015-2025 project. The goal of PEHKO (improving maintenance practices and policies on paved roads) is to increase the lifetime of the road pavement, and thus cut down annual paving

DDM Holding AG: Q3 and YTD report January - September 2018

Record collections and successful refinancing lowering the cost of fundingHighlights third quarter 2018 œ  Net collections increased by 153% to EUR 16.8M (Q3 2017: EUR 6.6M) œ  Cash EBITDA increased by 188% and amounted to EUR 14.7M (Q3 2017: EUR 5.1M) œ  Adjusted net profit for the period of EUR 0.3M excluding non-recurring items** œ  Gross ERC at the end of September 2018 was EUR 250M (Q4 2017: EUR 250M) œ  Cash on hand available for investments at the end of September 2018 was EUR 50M Highlights nine months 2018 œ  Net collections increased by 74% to EUR 42.9M (9M

DDM Debt AB: Q3 and YTD report January - September 2018

Record collections from portfoliosHighlights third quarter 2018 œ  Net collections increased by 158% to EUR 16.6M (Q3 2017: EUR 6.5M) œ  Cash EBITDA increased by 209% to EUR 15.0M (Q3 2017: EUR 4.8M) œ  Adjusted net profit for the period of EUR 0.3M excluding non-recurring items ** œ  Cash on hand available for investments at the end of September 2018 was EUR 49M Highlights nine months 2018 œ  Net collections increased by 91% to EUR 42.5M (9M 2017: EUR 22.3M) œ  Cash EBITDA increased by 109% to EUR 37.5M (9M 2017: EUR 17.9M) œ  Adjusted net profit for the period of

Interim Report January – September 2018

BioArctic reports strong BAN2401 Phase 2b results for Alzheimer patients. AbbVie exercises its option to a license for Parkinson’s projectsJuly – September 2018 · Net revenues for the period amounted to SEK 94.0 million (31.5) · Operating profit amounted to SEK 33.1 million (0.6) · Profit for the period amounted to SEK 25.9 million (-0.1) · Earnings per share were SEK 0.29 (0.00) · Cash flow from operating activities amounted to SEK -31.5 million (-23.6) January – September 2018 · Net revenues for the period amounted to SEK 198.6 million (89.7) · Operating profit

IRRAS AB (PUBL) INTERIM REPORT JANUARY–SEPTEMBER 2018

Preparation for US launch of IRRAflow® ongoing, CE mark catheter re-certification now expected at YE 2018 Third quarter, July–September 2018 · Net revenue totaled SEK 0.0 million (11.3). · Operating loss (EBIT) amounted to SEK -40.0 million (-7.2). · Loss after tax totaled SEK -41.8 million (-7.3). · Earnings per share before and after dilution amounted to SEK -1.75 (-0.42). Full year to date January–September 2018 · Net revenue totaled SEK 6.0 million (11.3). · Operating loss (EBIT) amounted to SEK -93.2 million (-37.8). · Loss after tax totaled SEK -88.8

Chevron Lummus Global and Neste Engineering Solutions enter into a joint collaboration

Neste Corporation News 8 November 2018 at 9 am (EET) Chevron Lummus Global (CLG) and Neste Engineering Solutions have signed a collaboration agreement regarding NAPCON operator training simulators for residue hydrocracking technologies. The agreement will cover all the residue hydrocracking technologies of Chevron Lummus Global, for example LC-FININGTM, LC-Max®, LC-SLURRY. The purpose of this collaboration is to offer solutions for all end-customer training solution needs for operating residue hydrocracking. Simulator based training is an effective learning method at

Interim Financial Report - Cinnober Financial Technology AB (Publ)

January 1, 2018 – September 30, 2018Third quarter highlights · Net revenue amounted to SEK 89.8 million in Q3/18, a year-on-year increase of 4.9% and a quarter-on-quarter increase of 2.5%. A majority of the revenue growth in the quarter is explained by a positive foreign exchange impact. The underlying cost base amounted to SEK 101.8 million, a 10.0% reduction year-on-year and a 20.6% reduction quarter-on-quarter. · Adjusted (underlying) EBITDA amounted to SEK -8.2 million, an improvement from the SEK -18.6 million reported in Q3/17 and the SEK -31.4 million reported in Q2/18. The

Revenio Group Corporation: INCREASED NUMBER OF SHARES ENTERED INTO TRADE REGISTER

Revenio Group Corporation, Stock Exchange Release, November 8, 2018 at 9:00 INCREASED NUMBER OF SHARES ENTERED INTO TRADE REGISTER Total of 50,856 new share subscriptions based on the company's 2015A stock options approved by the Board of Directors of Revenio Group Corporation on October 24, 2018, have been entered into the trade register today. The share subscription price under 2015A option rights was 8.23 EUR per share. The subscription period for 2015A options is May 31, 2017-May 31, 2019. After these subscriptions, the number of Revenio Group Corporation's shares and votes

INVITATION TO PRESENTATION OF Q3 2018 RESULTS

Techstep ASA will release its third quarter 2018 results on Thursday 15 November 2018 at 7.00 am CET. The quarterly report and presentation will be made available on the company’s website www.techstepasa.no and www.newsweb.no. CEO Jens Haviken and CFO Marius Drefvelin will present the company’s results at 10:00 am CET at Hotel Vika Atrium, Munkedamsveien 45, in Oslo, Norway. The presentation will be given in Norwegian, with supporting material in English. The presentation can also be followed through live audio webcast. Webcast – audio and slide presentation   Please join the Q3

TECHSTEP ASA: Q3 2018 RESULTS

Highlights third quarter 2018 · Revenue increased 45% year over year to NOK 261.6 million in Q3 2018, driven by growth in Norway · EBITDA of NOK 10.9 million (4.2%) vs. Q3 2017 EBITDA of NOK 5.4 million (3.0%). The EBITDA level continues to reflect growth investments and integration costs · Awarded new contracts with a potential total value of NOK 242 million in Q3 and NOK 765 million YTD 2018 · Completed acquisition of Wizor AS, enabling Techstep to provide high-end cyber security solutions CEO comments “We delivered solid growth in the third quarter. Revenue increased

IK invests in Infradata

IK Investment Partners (“IK”), a leading Pan-European private equity firm, is pleased to announce that the IK VIII Fund has acquired a majority stake in Infradata Group (“Infradata”) from Waterland Private Equity Fund V (“Waterland”). Infradata is a leading provider of cybersecurity and secure networking solutions across Europe. Financial terms of the transaction are not disclosed.Infradata was founded in the Netherlands in 2004, where it continues to be headquartered. The company has an additional presence in Germany, UK, France (Nomios), Belgium, Poland and the US, with ambitious

Flipped classroom enhances learning outcomes in medical certificate education

The quality of medical certificates written by students of medicine was better when they were taught by using the flipped classroom approach instead of traditional lecturing. A randomly selected student from the flipped classroom group had an 85% probability to receive a better total score than a student from the traditional teaching group, according to a new study from the University of Eastern Finland.  One of the goals of medial training is to provide students with good skills in writing medical certificates and medical statements. In Finland, permanent residents are covered by social

There are no items matching the current filter
There are no more items matching the current filter
Back to top